Answers are grounded in this paper and cite their sources.
ECD is a rare life-threatening, slowgrowing blood cancer called a histiocytic neoplasm, characterized by infiltration of non-Langerhans cell and by clonal expansion of histiocytes. The unknown etiology of ECD, the wide variety of its clinical features and manifestations that often-mimicking other diseases, lead to the obscure and diagnostically elusive properties of this disorder, and support it classification as a form Langerhans Cell Histiocytosis (LCH). The overproduction of histiocytes (histiocytosis), and xanthogranulomatous infiltration in critical organs leads to inflammation that causing multisystem failure. Histologically, it was observed an infiltration of tissues by sheets of foamy CD68 (+) CD1a (-) histiocytes on biopsy specimen, this finding is critical for definitive diagnosis of ECD. Nevertheless, histiocytes are large phagocytic cells that help fight infection and destroy foreign substances. There are plethora of hypotheses and decades of debate about whether ECD is a neoplastic or immune disorder. Indeed, ECD neither considered a hereditary or contagious disease. In 2016 the World Health Organization recognized ECD as a blood cancer. Molecular findings, cancer-causing DNA mutations in V600E BRAF and other mutations of the MAPK (MARPK1) and PIK3 pathways (NRAS, PIK3CA) altogether pointed to a neoplastic, rather than inflammatory, nature of the disease. Herein, we mustered and overviewed the facts about a panoramic consolidation of all the various events concerning ECD. We shed light also on the upheaval BRAF inhibitors treatment that demonstrate efficacy and gave longer prognosis than expected for our patient. There is a departure from the norm regarding the survival continuity of more than 15 years concerning our patient by Vemurafenib.
No takes yet. Share an insight, caveat, or question.
Bowirrat et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: